{'fraction_non_alphanumeric': 0.035217359959628, 'fraction_numerical': 0.01838367817749261, 'mean_word_length': 5.302362562471604, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 5, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences

The treatment landscape for gastric cancer (GC) is constantly evolving with therapies affecting all aspects of health-related quality of life (HRQoL) which need careful monitoring. While there are HRQoL measures designed specifically to capture issues relevant to patients with GC, these might be outdated and only relevant to patients in westernised cultures. This review identifies the patient-reported measures used to assess HRQoL of patients with GC and compares the HRQoL measures used across cultures including East Asia, where GC is more prevalent. We conducted a systematic review of publications between January 2001 and January 2021. A total of 267 papers were identified; the majority (66%) of studies involved patients from East Asian countries. Out of the 24 HRQoL questionnaires captured, the European Organisation for Research and Treatment of Cancer Core Cancer measure (QLQ-C30) was the most widely used (60% of all studies and 62% of those involving patients from East Asian countries), followed by its gastric cancer-specific module (QLQ-STO22, 34% of all studies and 41% from East Asia). Eight questionnaires were developed within East Asian countries and, of the 20 studies including bespoke questions, 16 were from East Asia. There were six qualitative studies. HRQoL issues captured include diarrhoea, constipation, reflux, abdominal pain and abdominal fulness or bloating, difficulty swallowing, restricted eating, and weight loss. Psychosocial issues related to these problems were also assessed. Issues relating to the compatibility of some of the westernised measures within East Asian cultures were highlighted.


Introduction
Gastric Cancer (GC) is one of the world's most prevalent and deadliest cancers. In 2018, GLOBOCAN estimated 783,000 deaths attributable to GC [1]. In East Asia: Japan, China, Korea, Mongolia, Taiwan, and Macau, the incidence of GC is higher than in Europe [1,2]. In 2018, South Korea, Mongolia, Japan, and China constituted the top four countries contributing the highest rates of GC per 100,000 of the population [1] and only one European country, Belarus, figured in the top ten. Due to routine screening for GC, patients from 1 3 Asia are frequently diagnosed earlier than their European counterparts [2].
The treatment strategy for GC has dramatically changed in the last 10-15 years [2]. Endoscopic or surgical resection is recommended for early tumours [2]. New perioperative treatments have been introduced including the FLOT regimen, 5-fluorouracil, leucovorin, oxaliplatin and docetaxel, with improved survival compared to previous chemotherapy regimens [3]. New targeted agents include anti-angiogenic compounds, trastuzumab combined with platinum and fluoropyrimidine-based chemotherapy for HER-2-positive patients [2], as well as checkpoint inhibitors administered for advanced disease [4,5]. Contemporary operative treatments using less-invasive approaches have also been introduced, including laparoscopic and robotic surgery. These systemic treatments and surgical advances may have more favourable outcomes in terms of treatment-related toxicities; however, they have unusual side effects previously not seen, including skin rashes, mucositis, and peripheral neuropathy [6,7] while surgical-related side effects include 'dumping syndrome', reactive hypoglycaemia and chronic nutritional problems [8][9][10][11].
Treatment-related side effects can have a widespread impact on HRQoL, including physical health, psycho-social well-being, relationships, and independence [12][13][14][15]. Complications need to be monitored to implement management strategies, treatment modification or cessation, which is critical from the Healthcare Professional perspective [16,17]. While the Common Terminology Criteria for Adverse Events (CTCAE) [18] represents the gold standard clinician rated tool for reporting severity of adverse events in clinical trials, patient-reported outcome measures (PROMs) consider HRQoL from the patient's perspective. Examples of PROMS used in GC include the generic, non-cancerspecific, instruments, such as the Medical Outcomes Survey Short Form survey (SF-36) [19] and the EuroQol group EQ-5D [20] and the cancer-specific measures, such as the Functional Assessment of Cancer Therapy (FACT-G) [21] and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (QLQ-C30) [22]. While these measures allow for comparisons across disease and tumour sites, they might overlook the specific and relevant concerns of patients with a particular cancer type such as GC.
Questionnaires designed to capture the HRQoL issues of specific relevance to patients with GC, include the EORTC and FACT gastric cancer-specific modules QLQ-STO22 [23,24] and the FACT-Ga [25], both designed to supplement their core measures QLQ-C30 and FACT-G. The Gastrointestinal Quality of Life Index (GLQI) [26] and the Post-gastrectomy Syndrome Assessment Scale-45 (PGSAS-45) [27] represent condition specific measures, applicable to gastrectomized patients. These measures are predominantly westernised. The Quality of Life Instruments for Cancer Patients: STomach cancer (QLICP-ST) [28] was developed in response to reported shortcomings of Westernised measures using some items incompatible with Chinese culture, but to date has not been widely applied. Of the Westernised measures, the QLQ-STO22 and FACT-Ga are the most well-known within the field. The QLQ-STO22 includes 22 questions covering five domains: dysphasia; pain/discomfort; dietary restrictions; upper gastro-intestinal symptoms; specific emotional problems; and three single items: dry mouth; body image and hair loss. Although the QLQ-STO22 was developed in westernised cultures, including the UK, France, Germany, and Spain, its use is evolving [29], and it has now been used in multiple trials worldwide and clinically validated to assess the importance of included items in Japan [29,30], Taiwan (Chinese version) [31], Mexico [32] and Iran [33].
Since GC is more prevalent in East Asia [2], it is important to understand whether the current HRQoL measures applied, like the QLQ-STO22 and FACT-Ga, are relevant to East Asian countries or whether any treatment or culturally specific adaptations or additions are needed. The way in which illness, such as cancer, is perceived and experienced is shaped by cultural and social context [34][35][36]. In a comparison between HRQoL of patients with breast cancer in the Netherlands and Japan, those from Japan reported better functioning while global quality of life scores were similar. It was suggested that in Japan, the quality of close relationships may contribute more to well-being than in European societies, while for women in western societies, achieving career goals and financial success or career may be more important. A further consideration relates to cross-cultural differences in access to healthcare resources and the economic burden of cancer experienced by patients. These differences need to be taken into account when considering HRQoL assessment across cultures. Studies exploring how HRQoL scales function across groups found differences in understanding [36]. HRQoL measures as well as differences in language assessment and linguistic equivalence including acceptability and interpretation of language [37].
This systematic review forms part of a programme of research addressing whether measures developed within westernised cultures, such as the STO22 cover the issues of relevance and importance to patients with GC in East Asia where GC incidence is highest. The following objectives are addressed in this review: 1. Identify the measures used to assess HRQoL in GC; 2. Examine cross-cultural differences in the assessment and reporting of HRQoL issues; 3. Identify challenges in the application of HRQoL measures across cultures.

Methods
This systematic review was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [38] framework.

Searches and information sources
Searches for publications on patients with GC or esophagogastric Junction Carcinoma (EGJC) within 2 cm of the esophagogastric junction, ≤ 1 year since treatment were carried out. A detailed search of four databases: MEDLINE (Ovid SP), CINAHL Complete (EBSCO host), PsycInfo (EBSCO host) and EMBASE (EBSCO host) was conducted to search for literature published between January 2001 and January 2021. The start period of 2001 was used as a cut-off, based on the date of an earlier systematic review carried out by Vickery and colleagues on behalf of the EORTC Quality of Life Group [23] to inform the development of the QLQ-STO22.
Search expressions were created using the Boolean operator OR between each term in each area and the Boolean operator AND between each area (see Table 1). Care was taken to adapt search expressions for different databases as necessary. The reviewers were also vigilant with respect to identifying new search terms during the review process.
Database searches were supplemented by manually checking references of selected full-text papers. Papers reporting cancers of multiple origins were included if separate data were reported for gastric cancer patients. Quantitative and mixed methods design studies were included as well as those using qualitative methods to capture HRQoL issues or patient-reported symptoms related to GC in any country. Conference proceedings, theses, cost-effectiveness studies and other papers reporting on studies which were not primary studies were excluded. Full details of inclusion criteria are provided in Table 2. All criteria had to be satisfied for a paper to be included.

Paper selection
Database search results were imported into Endnote [X8] and de-duplicated. All references (titles and abstracts) were subsequently transferred to Rayyan QCRI (rayyan.qcri. org), an online systematic review management platform, and a thorough screening process conducted. In stage one, two independent reviewers [AR, SS] reviewed all title and abstracts in Rayyan against the inclusion criteria ( Table 2) for full-text review and any discrepancies were resolved. In the event of any remaining doubt, the full paper was obtained. At stage two, all full texts were reviewed by AR and independently double-screened by a second reviewer [SS, MT, MG, KD, CM, BA]. A third reviewer resolved any eligibility disagreements. Inter-rater agreement percentage was reported.

Data extraction and analysis
A standardised form for data extraction, adapted from the minimum data checklist [39], was created in Microsoft Excel. All extracted data were reviewed by AR and checked by a second reviewer [SS]. Carefully targeted data extraction included: patient group, patient-reported measures used including HRQoL instruments and bespoke questions; geographical location of studies and patient-reported HRQoL issues and symptoms identified in results sections of papers. New issues that were either not covered by existing measures, or that authors reported as novel were also recorded. Measures used to evaluate these issues were recorded. Culturally specific factors were identified by reviewing the narrative provided by authors in the results and discussion sections of papers. Papers reporting studies from East Asia were categorised as those originating from countries based on the World Population review [40] (see Table 2 for the full list).

Results
The database searches generated 12,304 hits ( Fig. 1). During stage 1, 6850 titles and abstracts were screened and 5809 of these were excluded. There was a high level of inter-rater agreement between reviewers (98%; 6752/6850). Screening identified 1041 full-text papers for review and 10 identified through checking full-text paper references. Interrater agreement for full-text reviewing was 92.3%. Altogether, 1051 full-text papers were reviewed and 784 were The remaining papers represented 92 (34%) studies from countries outside of East Asia including: 10 from Germany, 7 Italy, 6 Poland, 5 Sweden, 4 the UK, 3 Spain, France, and Portugal, 2 Turkey, 7 Europe; 10 from Iran, 7 the USA, 4 Canada and India and 2 Colombia. The following countries included only one study: Finland, Vietnam, Singapore, Greece, Switzerland, Lithuania, Serbia, Ireland, Greece, Israel, and Australia. Papers reported mostly trials (127; 48%), e.g., comparing treatment protocols, nutritional supplements or management strategies; cohort studies (62; 23%); prospective studies (38; 14%); and the development and validation of HRQoL measures (9; 3%). Studies also reported on coping strategies, adjustment and acceptance of GC, nutritional status, unmet needs, and educational and self-care interventions. Six papers [23,[41][42][43][44][45], including 5 from non-East Asian countries, reported qualitative studies; three involved interviews with patients about symptoms experienced, such as gastrointestinal problems, fatigue, weight loss, and dietary restrictions, [41][42][43] and one about treatment preferences [44] whereby maintenance of selfcare and minimising toxicities were rated as priorities. Two incorporated qualitative methodologies as part of a questionnaire development process [23,45].
In addition to bespoke questions added to match the researchers' areas of interest, eight measures [27,28,45,[54][55][56][57][58], were developed in East Asia, and the PGAS45 [27] includes clinically important items selected by the Japan Post-gastrectomy Syndrome Working Party. Across all measures, the most widely assessed construct pertains to physical symptoms and this is particularly true for the GC or gastrointestinal specific measures which focus on gastrointestinal symptoms of disease and treatment such as gastrectomy. General physical symptoms assessed (e.g., by the EQ5D, QLQ-C30, FACT-G) [5,21,22] which are not necessarily cancer or GC-specific include mobility, nausea, vomiting, appetite and weight loss, diarrhoea, constipation fatigue, energy, sleeping problems, and pain. GC-specific symptoms assessed (e.g., by the FACT-Ga, QLQ-STO22, and the Symptom-Focused Quality of Life Questionnaire for Gastric Cancer Patients after Gastrectomy (KOQUSS-40)) [23][24][25] include reflux, difficulty swallowing (dysphagia), dry mouth, eating and dietary restrictions, taste, abdominal pain and fullness, and dumping syndrome, with the PGSAS45 [27] distinguishing between early and late symptoms. The impact of symptoms on functioning is also assessed and, in particular, captured by the generic measures (e.g., by the EQ5D, SF-36, Spitzer Quality of Life Index, the 15D, QLQ-C30 and FACT-G) [19-22, 60, 61].

Cross-cultural differences in the assessment and reporting of HRQoL issues
As mentioned above, the EORTC measures (QLQ-C30 and QLQ-STO22) were the most frequently used across all studies and this was also the case for studies conducted within East Asian countries. The QLQ-C30 was the measure of choice in 62% of studies involving patients from East Asia and the QLQ-STO22 in 41% of studies in East Asia. Of the eight measures developed within East Asian cultures, only the Korenaga Scale score/Wu's adapted special score [56,57] and the GERD QOL Scale [59] have been applied in studies involving patients outside of East Asia. In addition, of the 20 studies including bespoke questions or scales, 16 (80%) were conducted within East Asia.

Challenges to the assessment of HRQoL in GC across cultures
Cultural influences on HRQoL assessment were reported in terms of differences across cultures in treatment protocols, health disparities, access to health care resources, cultural views and practices, environmental and psycho-social issues, and linguistic equivalence. Potential environmental factors reported to impact HRQoL included pollution [63] and economic burden, especially for Chinese patients [35]. There were poignant cultural differences even surrounding the conceptualisation of cancer. In some East Asian studies cancer and malignancy were not culturally acceptable topics for discussion [32] and there was a social stigma linked to GC. Lee and colleagues [56,64] compared HRQoL of Canadian Western and Korean patients and reported lower HRQoL in Korean patients. They suggested that as group participation is an integral part of Korean culture and cancer patients have been known to have to leave their jobs and miss group activities because of their cancer, this might be a significant impact for patients from Korea. Discussion of family and practical problems, spirituality, religion, and sexuality were reported as culturally sensitive and potentially upsetting for some communities [34,35]. As part of a validation Studies often use more than one measure study of the FACT-Ga in Japan [65], the proportion of missing responses to the sex life question "I am satisfied with my sex life", was highlighted with only 40.5% of respondents answering the question. Several validation studies exploring the design and content validity of the QLQ-C30 and QLQ-STO22 promoted their validity for use in East Asian culture [30,31,66]. Whilst the overall validity of the most widely used GC-specific measures was confirmed, there were reported issues around linguistic equivalence in terms of acceptability and interpretation of language. For example, Huang and colleagues [31] suggested that the QLQ-C30 and QLQ-STO22 measures held the potential to positively impact understanding of well-being in patients from Taiwan, but that questions in the eating restriction scale, may hold different meaning for Taiwanese patients. Validation studies in Mexico [32] and Iran [33], also noted favourable outcomes on most scales of the QLQ-STO22, other than low internal consistency for "have you had trouble enjoying your meals?". It was noted [33] that patients understood the translation of the question about enjoyment of meals but suggested that it might mean something different in Persian culture compared to in Western cultures. Restrictions to eating or meal-related issues, were widely documented in the literature and there were occasional adaptations to measures linked to East Asian food and culture. For example, Morita et al.'s validation study of the QLQ-STO22 [30], suggested validity for use in Japan, however, they recommended that the question referring to a 'bloated feeling' should be replaced with one referring to 'retaining gas'. Furthermore, they speculated that problems linked to dysphagia and early satiety, might be linked to a staple Japanese food, rice, as patients might experience problems enjoying meals because of the need to eat a liquidised form of rice. Garland and colleagues [25] reported that patients found it difficult when questions included the word "stomach" if they had experienced a total gastrectomy and thus removed questions including this word from the Asian version of the FACT-Ga. Reference to cultural practices including traditional Chinese Medicine (including acupuncture, Tai Chi and herbal medicines) and its link to improved HRQoL was a noteworthy feature of several East Asian studies, principally from China [58,67,68]. Quan et al. [58] explored HRQoL issues for GC patients by implementing their HRQoL measure for traditional Chinese Medicine for advanced GC to measure the benefits of Chinese medicines for chemotherapy or surgical symptoms. The merits of a measure developed to capture the nuances of Chinese culture, the QLIP-ST [28] were highlighted in a comparison with the QLQ-STO22 [23,24] in terms of enhanced compatibility with Chinese cultures, clearer structure, greater precision, and ease of interpretation [28].

Discussion
Our review captures the measures used to identify the full range of HRQoL issues faced by people with GC. The review generated 267 studies using patient-reported HRQoL measures with patients with GC who had recently finished treatment (within a year). Two thirds of these studies were from East Asia, which given the higher prevalence of GC in this part of the world is unsurprising [1,2]. Measures developed with patients and health care professionals from European countries (QLQ-C30 and QLQ-STO22) were the most widely used and thus the patientreported HRQoL issues reported in the studies are largely a function of the items included in these measures. Overall, studies conducted in East Asia applied more GC-specific measures, mainly using the QLQ-STO22, compared with studies conducted in countries outside of East Asia. This might again be accounted for by the high and emerging incidence and interest in GC treatment in East Asia, evidenced by the fact that 88% of studies in East Asia identified in this review were conducted since 2010, with the vast majority conducted post-2015. Our findings suggest that the measure of choice does not vary between countries and while the validity of the westernised measures has been queried in some papers (e.g., [28,55,64]), evidence suggests that these measures were widely accepted [30,33]. In non-westernised countries, some content validity issues were noted especially around linguistic equivalence and problems in translating questions in the 'eating restrictions' [30,31,33]. Questions in these domains may need reassessing in countries outside of East Asia. Eight measures were developed for patients within East Asia and 16 of the 20 studies including bespoke measures were from East Asia suggesting that the existing and widely used westernised measures might have important omissions, such as symptoms relating to dumping syndrome or need adapting to suit East Asian culture.
Several issues were only reported through ad hoc measures or in interview studies, including changing emotions surrounding food [41] and family communication issues [53]. These studies are particularly informative for providing additional depth, as patients have the freedom to talk about issues of concern to them, rather than responding to a set of pre-defined issues in a questionnaire.
Sexuality and sexual activity were rarely explored in the literature, irrespective of geographic region. Again, this might be a function of these issues not being asked about in the most widely used measures, such as QLQ-C30 and QLQ-STO22. Another possible explanation might link to the cultural unacceptability of discussing sexuality and sexual activity as a topic, particularly in East Asia and the difficulties in applying the sexual well-being scale of the FACT-Ga noted by Maeda and colleagues [65]. More research is needed to explore how acceptable patients with GC find it to be asked about the impact of their cancer on sexuality and whether there are geographical variations. Other overlooked issues included spiritual and religious topics and family communication, and, as with sexual functioning, there are potential cultural differences around acceptability about discussing these issues with less acceptability in some East Asian cultures. Further research is needed to quantify whether there are differences between non-Westernised and Western countries, surrounding these topics.
The impact of traditional Chinese Medicine on HRQoL was an expected feature of the East Asian literature given the high regard placed on traditional practices and one measure specific to capturing the HRQoL issues based on traditional Chinese Medicine [58] was identified in this review. There were also issues relating to language used with the perceived unacceptable use of the word stomach resulting in its removal from the Asian FACT-Ga [25]. Interestingly, the word stomach is also referred to in the widely used QLQ-STO22, but no studies reported this as problematic, although this may be because critiques of measures are rare. Similarly, preferences for using phrases such as 'retaining gas', rather than a 'bloated feeling' were occasionally voiced by patients [30]. Further research is needed to explore the cultural acceptability of HRQoL measures, and linguistic equivalence issues.

Limitations
During the selection process, 90 non-English language papers were excluded and many more were automatically excluded as a function of the filter option of database searches, thus we might have overlooked some pertinent issues and measures reported in studies in East Asia. Although we provide an overview of the measures used and thus HRQoL issues reported by patients with GC, our overview of issues is limited by the questions included in the measures; there were only six qualitative studies which offer additional insight into the HRQoL experience of patients. In addition, comparisons in the HRQoL of patients across cultures are limited; we were in a position to compare HRQoL measure usage across cultures rather than differences in the incidence of HRQoL concerns according to culture. This review is also limited by its descriptive focus, and the heterogenous nature of the studies, in terms of methods and measures used and focus and context of the studies. This makes it difficult to make comparisons between studies and ensure issues have not been missed. We have however provided a comprehensive overview of the measures used to assess patient-reported outcomes in GC patients from East Asian countries and countries outside of East Asia but given emerging treatments and new or adapted patient-reported HRQoL measures, we recognise the need for an on-going evaluation of patient-reported issues.

Conclusion
To our knowledge, this review is the first to provide a comprehensive overview and comparison between East Asia and non-East Asia in HRQoL measures used for GC. Measures provide extensive coverage of HRQoL issues covering issues across physical, social, and psychological domains. The EORTC measures (QLQ-C30 and QLQ-STO22) are the most widely used irrespective of geographical location. While these measures benefit from extensive testing as part of their validation, they were not developed and tested with people from East Asia. Measures developed within East Asian cultures and bespoke questions and instruments offer improved sensitivity to the nuances of East Asian cultural and social contexts and allow for further exploration of psycho-social issues as well as symptoms relating to dumping syndrome or novel treatments. Further research is needed on the cultural relevance of HRQoL measures as well as further consideration of how we might make measures more culturally adaptable and acceptable.
Author contributions ASD, AR, SS, MT and VV conceived the idea for the work and wrote the systematic review protocol. AR carried out the literature searches and AR, SS, MT, MG, CM, BA, and KD reviewed the manuscripts for inclusion/exclusion. All authors were involved in the writing and reviewing of the manuscript. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.